Eom Pharmaceutical Holdings Inc (IMUC)

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company listed on OTC Markets under the ticker IMUC as common stock. The company focuses on developing drug candidates intended to address serious diseases and improve patient outcomes. Its lead program, EOM613, is a peptide-nucleic-acid-based compound with reported cytokine activity that has completed Phase 2 testing in indications including cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis. EOM613 has also been studied in a Phase 1/2 trial for infectious diseases such as COVID-19. The company is also advancing EOM 147, an investigational aminosterol that has completed Phase 2 testing in age-related macular degeneration, diabetic retinopathy, and macular edema associated with retinal vein occlusion. Founded in 2020, EOM Pharmaceuticals Holdings is headquartered in Montvale, New Jersey.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.